buprenorphine HCl buccal film - BBUP group	placebo group	From baseline to week 12 (primary endpoint), mean (SD) NRS (numerical rating scale) pain scores	17053	17271	NRS pain scores increased significantly more in the placebo group (1.92 [1.87]) than in the BBUP group (0.88 [1.79]), with a between-group difference (favoring buprenorphine) of −0.98 (95% CI, −1.32 to −0.64; P < 0.001
buprenorphine HCl buccal film - BBUP group	placebo group	From baseline to week 12 (primary endpoint), mean (SD) NRS (numerical rating scale) pain scores	16998	17288	From baseline to week 12 (primary endpoint), mean (SD) NRS pain scores increased significantly more in the placebo group (1.92 [1.87]) than in the BBUP group (0.88 [1.79]), with a between-group difference (favoring buprenorphine) of −0.98 (95% CI, −1.32 to −0.64; P < 0.001; Figs. 3 and 4).
buprenorphine HCl buccal film - BBUP group	placebo group	Pain control sensitivity analyses	17534	17865	All sensitivity analyses confirmed that pain control was superior in the BBUP group (Fig. 4) compared with the placebo group, including the MMRM (−1.15, P < 0.001), LOCF (mean treatment difference, −0.97 [95% CI, −1.27 to −0.66]; P < 0.001), and BOCF (mean treatment difference, −0.46 [95% CI, −0.73 to −0.18]; P = 0.001) analyses.
buprenorphine HCl buccal film - BBUP group	placebo group	Patient-reported impression of treatment benefit	19173	19418	Patient-reported impression of treatment benefit was significantly greater with BBUP: the mean (SD) PGIC score at week 12 was 4.5 (1.86) in the BBUP group vs 3.2 (1.98) in the placebo group (treatment difference, 1.3; 95% CI, 0.9-1.6; P < 0.001)
buprenorphine HCl buccal film - BBUP group	placebo group	responders achieving ≥50% pain reduction	18389	18682	A significantly greater proportion of patients in the BBUP group compared with the placebo group were classified as responders based on achieving ≥30% pain reduction (BBUP group, 64.2%; placebo group, 30.6%; P < 0.001) or ≥50% pain reduction (BBUP group, 39.5%; placebo group, 16.9%; P < 0.001
buprenorphine HCl buccal film - BBUP group	placebo group	responders achieving ≥30% pain reduction	18389	18607	A significantly greater proportion of patients in the BBUP group compared with the placebo group were classified as responders based on achieving ≥30% pain reduction (BBUP group, 64.2%; placebo group, 30.6%; P < 0.001)
buprenorphine HCl buccal film - BBUP group	placebo group	responders achieving ≥30% pain reduction	18389	18682	A significantly greater proportion of patients in the BBUP group compared with the placebo group were classified as responders based on achieving ≥30% pain reduction (BBUP group, 64.2%; placebo group, 30.6%; P < 0.001) or ≥50% pain reduction (BBUP group, 39.5%; placebo group, 16.9%; P < 0.001
buprenorphine HCl buccal film - BBUP group	placebo group	Pain control sensitivity analyses	17534	17659	All sensitivity analyses confirmed that pain control was superior in the BBUP group (Fig. 4) compared with the placebo group,
buprenorphine HCl buccal film - BBUP group	placebo group	Patient-reported impression of treatment benefit	19173	19419	Patient-reported impression of treatment benefit was significantly greater with BBUP: the mean (SD) PGIC score at week 12 was 4.5 (1.86) in the BBUP group vs 3.2 (1.98) in the placebo group (treatment difference, 1.3; 95% CI, 0.9-1.6; P < 0.001).
